Prostate Cancer | Tumor

John Litten: Participating on a PARP Clinical Trial for mCRPC

September 28th 2020

Talking About Gene Testing in Prostate Cancer

September 28th 2020

Testing for Mutations in Prostate Cancer

September 28th 2020

Prostate Cancer: Learning About Treatment Options

September 28th 2020

Receiving a Prostate Cancer Diagnosis

September 28th 2020

Metastatic Castration-Resistant Prostate Cancer Overview

September 28th 2020

The Future of PARP Inhibitors in Prostate Cancer

September 28th 2020

Patient’s Role in Decision-Making for Prostate Cancer

September 28th 2020

Quality of Life With Prostate Cancer

September 28th 2020

FDA-Approved PARP Inhibitors for Prostate Cancer

September 28th 2020

Impact of BRCA Mutations in Prostate Cancer

September 28th 2020

Genetic Counseling for Prostate Cancer

September 28th 2020

Diagnosis of Prostate Cancer

September 28th 2020

Smartphone App Encourages Smoking Cessation, House Passes Veteran’s Prostate Cancer Treatment and Research Act, and More

September 25th 2020

From a new study showing that the iCanQuit smoking cessation app is more likely to work than typical guidelines, to the House unanimously passing the Veteran’s Prostate Cancer Treatment and Research Act, here’s what’s happening in the cancer landscape this week.

Lynparza Significantly Improves Survival in Subset of Patients with Metastatic Prostate Cancer

September 23rd 2020

The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.

The Future of PARP Inhibitors in Prostate Cancer

September 16th 2020

Patient’s Role in Decision-Making for Prostate Cancer

September 16th 2020

Quality of Life With Prostate Cancer

September 16th 2020

FDA Approved PARP Inhibitors for Prostate Cancer

September 16th 2020

Impact of BRCA Mutations in Prostate Cancer

September 16th 2020

Genetic Counseling for Prostate Cancer

September 16th 2020

Diagnosis of Prostate Cancer

September 16th 2020

CURE® Speaking Out Launches Video Series in Recognition of National Prostate Cancer Awareness Month

September 8th 2020

Charles J. Ryan, M.D., internationally recognized for his research on prostate cancer, discusses risk factors, treatments and racial disparities associated with the disease.

The Latest News and Updates in Prostate Cancer

September 5th 2020

A roundup of the latest news and updates for patients with prostate cancer from CURE®.

Addressing Racial Disparities in Prostate Cancer

September 1st 2020

Learning About Advanced Prostate Cancer

September 1st 2020

Understanding Genetics and Genomics in Prostate Cancer

September 1st 2020

The Basics of Prostate Cancer

September 1st 2020

Genetics Remains Paramount for Moving Rare Cancers Forward

August 30th 2020

The evolving understanding of cancer genetics is allowing for clinicians to look at how to move rare cancer treatments, and identifications, forward.

FDA Offers Feedback on Phase 3 Trial Design of VERU-111 in Prostate Cancer

August 26th 2020

The Food and Drug Administration noted the trial design was acceptable for researchers to evaluate VERU-111 in in metastatic castration and novel androgen-blocking agent resistant prostate cancer.